Key Takeaways PBYI posted Q2 adjusted EPS of $0.15, beating estimates and reversing the year-ago loss.Nerlynx product sales rose 10.8% year over year to $49.2M, within management's guidance.2025 revenue outlook remains $212M-$222M, with Nerlynx sales expected to be in the range of $192M-$198M.Puma Biotechnology (PBYI) reported second-quarter 2025 adjusted earnings of 15 cents per share, which beat the Zacks Consensus Estimate of 11 cents. In the year-ago quarter, the company had incurred an adjusted loss of ...